European Union - English - EMA (European Medicines Agency)

pfizer europe ma eeig - pemetrexed disodium, pemetrexed disodium hemipentahydrate - carcinoma, non-small-cell lung; mesothelioma - antineoplastic agents - malignant pleural mesotheliomapemetrexed pfizer in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.non-small cell lung cancerpemetrexed pfizer in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.pemetrexed pfizer is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.pemetrexed pfizer is indicated as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.

European Union - English - EMA (European Medicines Agency)

pfizer europe ma eeig - pemetrexed ditromethamine - carcinoma, non-small-cell lung; mesothelioma - folic acid analogues, antimetabolites - malignant pleural mesotheliomapemetrexed hospira uk limited in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.non-small cell lung cancerpemetrexed hospira uk limited in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see smpc section 5.1).pemetrexed hospira uk limited is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see smpc section 5.1).pemetrexed hospira uk limited is indicated as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see smpc section 5.1).

European Union - English - myHealthbox

pfizer limited - crizotinib - hard capsules - 200 mg - carcinoma, non-small-cell lung - anti-neoplastic agents, protein kinase inhibitor - indicated for the treatment of adults with previously treated anaplastic lymphoma kinase (alk)-positive advanced non-small cell lung cancer (nsclc)

European Union - English - myHealthbox

pfizer limited - crizotinib - hard capsules - 250 mg - carcinoma, non-small-cell lung - anti-neoplastic agents, protein kinase inhibitor - indicated for the treatment of adults with previously treated anaplastic lymphoma kinase (alk)-positive advanced non-small cell lung cancer (nsclc)

European Union - English - EMA (European Medicines Agency)

pfizer limited - celecoxib - adenomatous polyposis coli - antineoplastic agents - onsenal is indicated for the reduction of the number of adenomatous intestinal polyps in familial adenomatous polyposis (fap), as an adjunct to surgery and further endoscopic surveillance (see section 4.4).the effect of onsenal-induced reduction of polyp burden on the risk of intestinal cancer has not been demonstrated (see sections 4.4 and 5.1)

European Union - English - EMA (European Medicines Agency)

pfizer ltd. - sitaxentan sodium - hypertension, pulmonary - antihypertensives, - treatment of patients with pulmonary arterial hypertension (pah) classified as who functional class iii, to improve exercise capacity. efficacy has been shown in primary pulmonary hypertension and in pulmonary hypertension associated with connective tissue disease.

European Union - English - EMA (European Medicines Agency)

pfizer limited - difloxacin - antibacterials for systemic use, antiinfectives for systemic use - turkeys; dogs; cattle; chicken - chickens:for the treatment of chronic respiratory infections caused by sensitive strains of escherichia coli and mycoplasma gallisepticum.turkeys:for the treatment of chronic respiratory infections caused by sensitive strains of escherichia coli and mycoplasma gallisepticum.also for the treatment of infections caused by pasteurella multocida.dogs:for the treatment of acute uncomplicated urinary-tract infections caused by escherichia coli or staphylococcus spp. and superficial pyoderma caused by staphylococcus intermedius.cattle:for the treatment of bovine respiratory disease (shipping fever, calf pneumonia) caused by single or mixed infections with pasteurella haemolytica, pasteurella multocida and / or mycoplasma spp.

European Union - English - EMA (European Medicines Agency)

pfizer europe ma eeig - bosutinib (as monohydrate) - leukemia, myeloid - antineoplastic agents, protein kinase inhibitors - bosulif is indicated for the treatment of adult patients with:newly‑diagnosed chronic phase (cp) philadelphia chromosome-positive chronic myelogenous leukaemia (ph+ cml).cp, accelerated phase (ap), and blast phase (bp) ph+ cml previously treated with one or more tyrosine kinase inhibitor(s) [tki(s)] and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.

European Union - English - EMA (European Medicines Agency)

pfizer europe ma eeig - varenicline - tobacco use cessation - other nervous system drugs - champix is indicated for smoking cessation in adults.

European Union - English - EMA (European Medicines Agency)

pfizer europe ma eeig  - palbociclib - breast neoplasms - antineoplastic agents - ibrance is indicated for the treatment of hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer:in combination with an aromatase inhibitor;in combination with fulvestrant in women who have received prior endocrine therapy.in pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone releasing hormone (lhrh) agonist.